Científica - Dr. Flavio Cárcano | Oncologia Clínica

Científica

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer

Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions

PD‑L1 expression and microsatellite instability (MSI) in cancer of unknown primary site

Precision medicine for urothelial carcinoma: An international perspective

Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels

Watch and wait policy remainsexperimental for the management ofrectal cancer

Phase III, Randomized, Double-Blind, Multicenter TrialComparing Orteronel (TAK-700) Plus Prednisone WithPlacebo Plus Prednisone in Patients With MetastaticCastration-Resistant Prostate Cancer That Has ProgressedDuring or After Docetaxel-Based Therapy: ELM-PC 5

What are the personal and professional characteristics that distinguishthe researchers who publish in high- and low-impact journals?A multi-national web-based survey

Metformin plus lrinotecan in patients with refractorycolorectal cancer: a phase 2 clinical trial

A phase 2 randomized clinical trial of abiraterone plusADT, apalutamide, or abiraterone and apalutamide inpatients with advanced prostate cancer with non-castratetestosterone levels (LACOG 0415)

Brachyury as a potential modulator of androgen receptor activityand a key player in therapy resistance in prostate cancer

An integrated tool for determining the primary originsite of metastatic tumours

Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin